Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 501 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Activation, Patient Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Interventions
Crenolanib besylate
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
Trametinib, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Neuroendocrine Tumor
Interventions
Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced May 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma
Interventions
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2042
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Recombinant Factor VIIa BI (rFVIIa BI)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Macrophage Activation Syndrome
Interventions
kineret, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced May 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
172
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 12:13 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Remote Patient Monitoring
Device
Lead sponsor
Tracy Jalbuena MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rockport, Maine
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced May 22, 2026, 12:13 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced May 22, 2026, 12:13 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
Behavioral
Lead sponsor
Family Medicine Residency of Idaho
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Caldwell, Idaho • Jerome, Idaho • Nampa, Idaho
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer (CRPC)
Interventions
BPX-101, AP1903
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Sepsis
Interventions
rPAF-AH
Drug
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions
PLX7486 TsOH
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced May 22, 2026, 12:13 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced May 22, 2026, 12:13 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
7
States / cities
Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Azacitidine, Gilteritinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced May 22, 2026, 12:13 AM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIA 28-6156
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
Not listed
U.S. locations
16
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Cerritos, California • Irvine, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 12:13 AM EDT
Completed Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Melanoma
Interventions
recMAGE-A3 + AS15 ASCI
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced May 22, 2026, 12:13 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8
Interventions
Atezolizumab, Brachytherapy, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Newport Beach, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 22, 2026, 12:13 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Stem Cell Transplant Patients
Interventions
ACTivate sessions
Behavioral
Lead sponsor
Anthony Sung, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
2
States / cities
Kansas City, Kansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 12:13 AM EDT